Join the premier forum for Hatch-Waxman litigators and pharmaceutical patent practitioners.

Widely recognized as the industry gold standard, this event unites leaders from brand-name and generic drug companies, alongside federal judges, the U.S. PTO’s PTAB, the FTC, and the FDA, to tackle the critical legal, regulatory, and business issues shaping pharmaceutical patent litigation. Focusing on pre-suit strategies, case filings, final adjudications, and everything in between, this conference provides unparalleled insights and actionable takeaways for navigating the complex and high-stakes world of Paragraph IV disputes. Join us to stay at the forefront of legal developments and connect with top professionals in this dynamic and evolving field.

Gain Insights on Evolving Policies, Industry Trends, and Litigation Strategies

  • Prepare for a New Administration
    Timely analysis and insights on the new administration’s policy priorities and the projected impact on small molecule IP.
     
  • Brand and Generic Focused Think Tanks
    TExplore the brand and generic point of view on how the small molecule manufacturers are evolving, emerging business concerns and litigation trends.
     
  • View from the Bench
    Our distinguished panel of District Court Judges will provide a closer look at the Paragraph IV litigation dockets.
     
Learn More

Key Conference Highlights

Status of the Inflation Reduction Act and Future Drug Price Negotiations

AI’s Impact on Drug Discovery and Patent Law

Focus on Litigation and Agency Decisions Following the Demise of the Chevron Doctrine in Loper V. Raimondo

Exploring the On-Sale Bar and Applicability of Prior Art

Orange Book Delisting Attempts

Navigating ODP and Patent Family Dynamics

View Agenda

3,700+

Attendees

560+

Speakers

110+

Sponsors

Key Conference Takeaways

Icon

Hear from FDA, FTC and other key government agencies about regulatory and enforcement priorities

Icon

Meet over a dozen leading senior in-house patent counsel from brands and generics

Icon

Learn from a Chambers-ranked “who’s who” of the Hatch-Waxman bar from New York, DC, and Chicago


Who You Will Meet

Patent attorneys and litigators (in-house & law firms) who represent:

  • Brand name pharmaceutical companies
  • Generic pharmaceutical companies
  • Biopharmaceutical companies

Earn CLE/Ethics Credits

Accreditation will be sought in those jurisdictions requested by the registrants which have continuing education requirements. This course is identified as non-transitional for the purposes of CLE accreditation.

Learn more

Questions?

Email us at [email protected]

Get in Touch

Ready to Register?

Secure your space now.

Register Now